loading
Schlusskurs vom Vortag:
$6.90
Offen:
$7.11
24-Stunden-Volumen:
752.69K
Relative Volume:
1.35
Marktkapitalisierung:
$381.64M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.4747
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
+15.52%
1M Leistung:
+93.70%
6M Leistung:
+83.64%
1J Leistung:
-9.01%
1-Tages-Spanne:
Value
$6.98
$7.475
1-Wochen-Bereich:
Value
$6.03
$7.475
52-Wochen-Spanne:
Value
$2.315
$10.13

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Firmenname
Fulcrum Therapeutics Inc
Name
Telefon
617-651-8851
Name
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Mitarbeiter
45
Name
Twitter
@fulcrumtx
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
FULC's Discussions on Twitter

Vergleichen Sie FULC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
7.07 330.35M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-23 Hochstufung Leerink Partners Market Perform → Outperform
2025-05-15 Hochstufung Cantor Fitzgerald Neutral → Overweight
2024-09-13 Herabstufung H.C. Wainwright Buy → Neutral
2024-09-12 Herabstufung BofA Securities Neutral → Underperform
2024-09-12 Herabstufung Cantor Fitzgerald Overweight → Neutral
2024-09-12 Herabstufung Leerink Partners Outperform → Market Perform
2024-09-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2024-09-12 Herabstufung Stifel Buy → Hold
2024-09-09 Hochstufung BofA Securities Underperform → Neutral
2024-05-20 Eingeleitet Cantor Fitzgerald Overweight
2024-03-13 Eingeleitet RBC Capital Mkts Outperform
2023-09-25 Eingeleitet Goldman Neutral
2023-08-23 Hochstufung H.C. Wainwright Neutral → Buy
2023-08-22 Hochstufung Stifel Hold → Buy
2023-05-04 Herabstufung Goldman Buy → Neutral
2023-03-10 Herabstufung Credit Suisse Outperform → Neutral
2023-03-10 Herabstufung H.C. Wainwright Buy → Neutral
2023-03-09 Herabstufung Stifel Buy → Hold
2023-02-28 Herabstufung Morgan Stanley Overweight → Equal-Weight
2023-02-24 Herabstufung BofA Securities Neutral → Underperform
2022-11-15 Eingeleitet Goldman Buy
2022-03-08 Eingeleitet Oppenheimer Outperform
2022-03-03 Hochstufung BofA Securities Underperform → Neutral
2021-08-11 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-22 Eingeleitet Credit Suisse Outperform
2021-03-02 Eingeleitet Stifel Buy
2020-10-16 Eingeleitet Piper Sandler Overweight
2020-08-12 Herabstufung BofA Securities Neutral → Underperform
2020-08-12 Bestätigt H.C. Wainwright Buy
2020-08-12 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-19 Herabstufung BofA/Merrill Buy → Neutral
2020-06-17 Eingeleitet BTIG Research Buy
2019-10-03 Eingeleitet H.C. Wainwright Buy
2019-08-12 Eingeleitet BofA/Merrill Buy
Alle ansehen

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

pulisher
01:23 AM

Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory - Insider Monkey

01:23 AM
pulisher
May 29, 2025

Fulcrum Therapeutics to Present at Upcoming Medical Meetings | FULC Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Fulcrum Therapeutics to Present at Upcoming Medical Meetings - Eagle-Tribune

May 29, 2025
pulisher
May 29, 2025

New Oral Sickle Cell Drug Shows Promise: Fulcrum to Reveal Phase 1 Trial Results at Global Medical Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

FULC: Piper Sandler Raises Price Target for Fulcrum Therapeutics | FULC Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Fulcrum Therapeutics to Participate in the 46th Annual Goldman S - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Rare Disease Innovator Fulcrum Therapeutics Takes Stage at Elite Goldman Sachs Healthcare Conference - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Fulcrum Therapeutics (FULC) Target Price Raised Amid Key Data An - GuruFocus

May 29, 2025
pulisher
May 27, 2025

Fulcrum gains as Leerink upgrades ahead of data for lead asset - MSN

May 27, 2025
pulisher
May 26, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partners - Defense World

May 26, 2025
pulisher
May 25, 2025

Leerink Partnrs Upgrades Fulcrum Therapeutics (NASDAQ:FULC) to Strong-Buy - Defense World

May 25, 2025
pulisher
May 24, 2025

Leerink raises Fulcrum Therapeutics stock to Outperform By Investing.com - Investing.com Canada

May 24, 2025
pulisher
May 24, 2025

Northern Trust Corp Buys 142,578 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

May 24, 2025
pulisher
May 23, 2025

Fulcrum Therapeutics Shares Rise After Upgrade From Leerink - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Fulcrum stock gains as Leerink upgrades (FULC:NASDAQ) - Seeking Alpha

May 23, 2025
pulisher
May 23, 2025

Fulcrum Therapeutics (FULC) Receives Analyst Upgrade and Increas - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Leerink Partners Upgrades Fulcrum Therapeutics (FULC) - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Leerink Upgrades Fulcrum Therapeutics to Outperform From Market Perform, Adjusts Price Target to $12 From $4 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Fulcrum Therapeutics (FULC) Receives Analyst Upgrade on Positive Outlook | FULC Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target - Insider Monkey

May 23, 2025
pulisher
May 21, 2025

Fulcrum Therapeutics at RBC Capital: Strategic Steps in Sickle Cell Treatment - Investing.com Canada

May 21, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Predicts FULC FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Raises Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

May 17, 2025
pulisher
May 17, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Upgraded by Cantor Fitzgerald - Defense World

May 17, 2025
pulisher
May 17, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Average Price Target from Analysts - Defense World

May 17, 2025
pulisher
May 15, 2025

Cantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Fulcrum Therapeutics Shares Rise After Cantor Fitzgerald Upgrade - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Fulcrum Therapeutics (FULC) Upgraded to Overweight by Cantor Fit - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight From Neutral, Price Target is $10 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FULC Stock Upgraded to Overweight by Cantor Fitzgerald with $10 Target | FULC Stock News - GuruFocus

May 15, 2025
pulisher
May 14, 2025

Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with P - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Fulcrum Therapeutics (FULC) Upgraded by Cantor Fitzgerald with Positive Outlook | FULC Stock News - GuruFocus

May 14, 2025
pulisher
May 12, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Dimensional Fund Advisors LP - Defense World

May 12, 2025
pulisher
May 10, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FULC Stock News - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Wells Fargo & Company MN Has $161,000 Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

May 10, 2025
pulisher
May 10, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 10, 2025
pulisher
May 10, 2025

Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025 - MSN

May 09, 2025
pulisher
May 09, 2025

Mariner LLC Buys Shares of 16,516 Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

May 09, 2025
pulisher
May 09, 2025

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 09, 2025
pulisher
May 08, 2025

Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsFULC - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

Fulcrum Therapeutics to Participate in Upcoming May Conferences - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Market Momentum Report: Fulcrum Therapeutics Inc (FULC)’s Negative Close at 5.35 - DWinneX

May 07, 2025
pulisher
May 06, 2025

Lobbying Update: $40,000 of FULCRUM THERAPEUTICS lobbying was just disclosed - Nasdaq

May 06, 2025
pulisher
May 05, 2025

Fulcrum Therapeutics (FULC) to Present PIONEER Data at Upcoming Conference Call | FULC Stock News - GuruFocus

May 05, 2025
pulisher
May 02, 2025

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - Sete News

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Fulcrum Therapeutics’ Positive Earnings Call Highlights - TipRanks

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss By Investing.com - Investing.com South Africa

May 01, 2025

Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Kapitalisierung:     |  Volumen (24h):